Volume 18, Number 3—March 2012
Hepatitis E Virus Infection in HIV-infected Persons
|Year of ALT increase||2001||1995||2000||2006||1989||1996||1996|
|Clinical presentation||Nausea, vomiting, abdominal pain, pale stools, dark urine||Fever, malaise, anorexia, diarrhea, dark urine, icterus||Fever, nausea, vomiting, diarrhea, abdominal pain, loss of appetite, malaise||Jaundice||Abdominal pain||Asymp||Asymp|
|Peak ALT, U/L||489||2,540||282||2,829||229||477||226|
|Alkaline phosphatase, U/L||80||153||99||409||157||125||137|
|Total bilirubin, mg/dL
|Hepatitis B virus core antigen||Neg||Pos||Pos||Pos||Neg||Pos||Pos|
|Hepatitis B virus surface antigen||Neg||Neg||Neg||Pos||Neg||Pos||Neg|
| Hepatitis C virus
|History of STI since HIV Infection||None||None||None||Syphilis and chlamydia infections||Gonorrhea||Syphilis||Gonorrhea|
|Duration of HIV, y||11||2||<1||13||2||8||9|
|CD4 count, cells/mm3||822||517||660||454||753||98||217|
|HIV RNA level, copies/mL||427||52,929||6,854||52,682||40,000||430,946||8,068|
|HEV serostatus||IgG sero and HEV RNA||IgG sero||IgM and IgG positivity||IgG sero||IgG sero||IgG sero||IgM with persistent positivity|
*All patients were male; none had evidence of acute hepatitis A virus infection or chronic HEV. HEV, hepatitis E infection; ALT, alanine aminotransferase; asymp, asymptomatic; AST, aspartate aminotransferase; neg, negative; pos, positive; STI, sexually transmitted infection; NK, none known; HAART, highly active antiretroviral therapy; sero, seroconversion.
†Patient was receiving monotherapy with zalcitabine.
‡Patient was receiving dual therapy with stavudine and ritonavir.
1Members are listed at the end of this article.
- Page created: February 16, 2012
- Page last updated: February 16, 2012
- Page last reviewed: February 16, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)